Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Completed
- Conditions
- Hepatic Carcinoma
- Registration Number
- NCT06245798
- Lead Sponsor
- Tang-Du Hospital
- Brief Summary
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. HCC patients with CPSH are heterogeneous and treatment allocation remains controversial. The aim of this study was to compare the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in these populations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
- HCC patients treated conventional liver resection or transarterial chemoembolisation
Exclusion Criteria
- (1) presence of types III/IV portal vein tumour thrombosis (PVTT), hepatic artery, biliary duct or inferior vena cava invasion; (2) presence of extrahepatic spread (EHS); (3) underwent previous treatments; (4) Eastern Cooperative Oncology Group Performance Status (ECOG-PS) >1; (5) diffuse tumor nodules; (6) combined with other tumours or severe cardiac, cerebral, and renal insufficiency; (7) non-Clinically significant portal hypertension（CSPH）, and (8) absence of baseline information
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival rate 5 year overall survival rate
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Tangdu hospital
🇨🇳Xian, Shaanxi, China
Xijing hospital
🇨🇳Xian, Shaanxi, China
Tangdu hospital🇨🇳Xian, Shaanxi, China